Dharam Kaushik

Objective To assess the safety and feasibility of robot‐assisted retroperitoneal lymph node dissection (R‐RPLND) and to compare the perioperative outcomes of R‐RPLND with open RPLND (O‐RPLND), as RPLND forms an integral part of the management of testis cancer and R‐RPLND is a minimally invasive treatment option for this disease. Materials and Methods The PubMed ® , Scopus ® , Cochrane Central Register of Controlled Trials, and Web of Science™ databases were searched for studies reporting perioperative outcomes of primary and post‐chemotherapy R‐RPLND and studies comparing R‐RPLND with O‐RPLND. Results The search yielded 42 articles describing R‐RPLND, including five comparative studies. The systematic review included 4222 patients (single‐arm studies, n = 459; comparative studies, n = 3763). Of 459 patients in the single‐arm studies, 271 underwent primary R‐RPLND and 188 underwent post‐chemotherapy R‐RPLND. For primary R‐RPLND, the operative time ranged from 175 to 540 min and the major complication rate was 4.1%. For post‐chemotherapy R‐RPLND, the operative time ranged from 134 to 550 min and the major complication rate was 8.5%. The conversion rate to open surgery was 2.2% in primary R‐RPLND and 9.0% in post‐chemotherapy R‐RPLND. In comparison with O‐RPLND, R‐RPLND was associated with a lower transfusion rate (14.5% vs 0.9%, P < 0.001) and a lower complication rate (18.5% vs 7.8%, P = 0.002). Conclusion Robot‐assisted RPLND has acceptable perioperative outcomes in both the primary and post‐chemotherapy settings but a notable rate of conversion to open surgery in the post‐chemotherapy setting. Compared with O‐RPLND, R‐RPLND is associated with a lower transfusion rate and fewer overall complications. Given the potential impact of selection bias, the optimal patient selection criteria for R‐RPLND remain to be elucidated.